TLNCW — Talon Capital Corp.

Nasdaq · Financials · Diversified Financial Services · CIK 2073340 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -342,807 1,971,217 257,162,549 2,653,957 10,419,158
Sep 2025 0 -159,097 383,939 252,862,213 3,096,635 10,368,532
Jun 2025 307,810 48,000 320,067
May 2025 89,798 25,000 81,255

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-301,327
Investing CF
$82,657
Financing CF
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
As of
2026-05-21

Balance + Analyst (yfinance extras)

Retained Earnings
$-7,551,478
Inventory
Receivables
$185,111
ST Investments
EBIT TTM
$-575,904
Pretax Income TTM
$2,355,156
Interest Exp TTM
Analysts

Annual Trend (SEC EDGAR, last 1y)

Revenues vs Net Income (last 1y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 255,100,876 10,328,702

Peers — same industry

TickerNameMarket CapLastDaily %
HASI HA Sustainable Infrastructure Capital, Inc. $4.84B $37.87
DMII Drugs Made In America Acquisition II Corp. $644.01M $10.11
EVAC EQV Ventures Acquisition Corp. II $480.98M $10.24
BCSS Bain Capital GSS Investment Corp. $479.32M $10.22
CEPF Cantor Equity Partners IV, Inc. $477.82M $10.41

News headlines (Yahoo Finance, 1h cache)

Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
2026-04-10 00:00 · Yahoo
Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
2026-01-13 01:43 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.